SCHEMBL12149684

SCHEMBL12149684

O=C(O)c1ccc(-c2cccc(O)c2)cc1OCc1cccc2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 1/20 0.70
▸ MCL1 Q07820 4/20 0.56
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ PARP10 Q53GL7 2/20 0.50
▸ PARP15 Q460N3 1/20 0.50
▸ FFAR1 O14842 1/20 0.46
▸ AKR1B1 P15121 1/20 0.46
▸ AKR1C3 P42330 1/20 0.46
▸ AKR1C2 P52895 1/20 0.46
▸ AKR1C1 Q04828 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.43
▸ KEAP1 Q14145 1/20 0.43
▸ NFE2L2 Q16236 1/20 0.43
▸ MRGPRX4 Q96LA9 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ PTGER4 P35408 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1378315 0.94 FDPS (0.78) FDPSMCL1MEN1KMT2APARP10
SCHEMBL12149699 0.92 FDPS (0.74) FDPSMCL1MEN1KMT2APARP10
SCHEMBL12149669 0.88 FDPS (0.67) FDPSMCL1MEN1KMT2APARP10
SCHEMBL12149693 0.88 FDPS (0.70) FDPSMCL1MEN1KMT2APARP10
SCHEMBL12149597 0.87 FDPS (0.66) FDPSMCL1MEN1KMT2APARP10
SCHEMBL12149685 0.87 FDPS (0.72) FDPSMCL1MEN1KMT2APARP10
SCHEMBL12149679 0.87 FDPS (0.72) FDPSMCL1MEN1KMT2APARP10
SCHEMBL12149601 0.86 FDPS (0.68) FDPSMCL1MEN1KMT2APARP10
SCHEMBL1375062 0.86 FDPS (0.65) FDPSMCL1MEN1KMT2APARP10
SCHEMBL12149608 0.86 FDPS (0.67) FDPSMCL1MEN1KMT2APARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 — — US disclosed
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 — — US disclosed
WO-2010043584-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS FDPS, GGPS1, COASY FDPS 1/4885MCL1 3077/4885MEN1 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback